Biogen Inc. Reports Strong First-Quarter Performance

Biogen Inc. has unveiled its financial results for the first quarter of fiscal 2025, showcasing a notable 6% increase in total revenue, reaching $2.4 billion compared to the same period in 2024.

Financial Highlights and Challenges

Despite the revenue growth, the company faced a downturn in GAAP diluted earnings per share, which decreased year over year to $1.64. Net income attributable to Biogen Inc. for the quarter ending March 31 was reported at $240.5 million.

CEO's Perspective on Growth Strategy

"Biogen delivered strong first-quarter results, supporting our strategy for long-term growth," stated CEO Christopher Viehbacher. He highlighted a significant transformation in the company's commercial product portfolio, with approximately 45% of total product revenue coming from key medicines outside of the MS business, signaling a strategic shift towards diversification.